The aim of this study was to evaluate whether a quantitative analysis of circulating t(14;18)-positive cells is of prognostic significance in patients with follicular lymphoma (FL) after myelo-ablative therapy supported by ABMT. We tested DNA from primary lymphoma tissue as well as PBMC before and after ABMT from 15 patients for the presence of the t(14;18) translocation. Nine patients showed a t(14;18) translocation, six patients were t(14;18)-negative. 
The mean overall survival of patients with follicular lymphoma (FL) including all stages is about 9 years.
1,2 Roughly 20% of the patients survive more than 15 years and relapsefree survival is also about 20% after 10-12 years. Almost all patients belonging to this group have been successfully treated by radiotherapy for low grade disease, mostly stage I and II and rarely IIIA. 1, 3 Between 15 to 60% of all patients with FL will ultimately undergo histologic conversion to a high-grade lymphoma, which has been associated in the majority of the patients with poor prognosis. [4] [5] [6] The relapse rate after initial treatment with various chemotherapy protocols is 10-15% per year. Fortunately, most patients respond to salvage therapy, but usually the disease-free interval after each remission is about half the previous remission duration. 1, 7, 8 Based on the high risk of relapse and of transformation even after having reached CR, myeloablative therapy supported by autologous stem cell transplantation has been introduced for patients aged less than 60 years as an early consolidation in 1st CR, as well as a treatment for relapse. Many institutions have used this approach, which seems to prolong the remission duration, but there is no proven evidence, that this treatment has an impact on overall survival. [9] [10] [11] [12] In addition, the influence of an in vitro treatment of bone marrow or peripheral blood derived stem cell preparations, as controlled by PCR for residual t(14;18)-positive cells, with regard to further outcome is not clear. [13] [14] [15] By cytogenetic studies, FL has been shown to be associated in 95% of cases with a typical translocation, the t(14;18)(q32;q21). 16, 17 Since the breakpoints cluster within the BCL-2 gene on chromosome 18 within small regions [18] [19] [20] and on chromosome 14 within the J-segments of the IgH locus, 21 a PCR technique has been established for the amplification of t(14;18) translocation fragments with a sensitivity up to one positive cell in 10 5-6 normal cells. [22] [23] [24] Therefore, this technique provides an excellent opportunity to monitor residual disease in specific situations, ie CR after radiotherapy, chemotherapy and after high-dose chemotherapy supported by bone marrow or peripheral stem cell transplantation, including bone marrow purging. 25 Molecular studies aimed at monitoring FL patients in CR after successful ABMT are hampered by some intriguing findings: (1) 29, 30 the multiple tube approach 31 or by increasing the DNA amount in a single PCR up to 5-10 g. 30 All these studies have shown, that many healthy individuals carry more than one t(14;18)-positive cell clone. 32 Comparable to EBVcarrying cells, t(14;18)-positive cell clones detected in healthy individuals seem to be long-lived. 30 Therefore, nucleotide sequence analyses are necessary to show that t(14;18)-positive cell clones detected in patients with FL in CR after myeloablative therapy carry the same translocation as the malignant cell clone found in the primarily affected lymph node.
Here we present clinical and molecular data obtained on 15 patients with FL treated in one center with myeloablative therapy and ABMT with a mean follow-up period of almost 4 years.
Patients and methods

Patients
The clinical characteristics of 15 patients which where treated with ABMT at the Department of Hematology and Oncology at the University of Freiburg between 1990 and 1993 are shown in Table 1 . At the time of bone marrow harvest and transplantation, five patients were already in complete clinical remission (CR), eight in partial remission (PR) and two patients had progressive disease (PD) (for definitions see Ref. 9) . Thirteen patients were treated with fractionated total body irradiation (FTBI), ie six fractions of 2 Gy each, and 60 mg/kg body weight of cyclophosphamide on 2 subsequent days. Two patients (P1 and P5) received treatment according to the BEAC protocol, 
In vitro purging of bone marrow
In the case of five patients, the bone marrow harvested for transplantation was purged because it contained more than 5% lymphoma cells based upon histological examination of the bone marrow biopsy. A mixture of five mouse monoclonal antibodies against the human B cells antigens CD19, CD20, CD22, CD23, and CD37 was kindly provided by Dr Dörken and Dr Haas (University of Heidelberg, Heidelberg, Germany). Bone marrow cells were incubated with the antibodies and in a second step with magnetic beads coated with sheep-anti-mouse IgG (Dynabeads M-450; Baxter Deutschland, Unterschleißheim, Germany). Antibodycoated cells were removed by using a magnetic separator (MAXSEP, Baxter Deutschland). The B cell-depleted bone marrow cells were resuspended in 150 ml MEM (minimal essential medium; Gibco BRL, Eggenstein, Germany) containing 10% human albumen and frozen after the addition of 150 ml freezing solution (6% HES, 5% DMSO, 4% human albumen). 33 Samples of 5 ϫ 10 6 cells were taken before and after purging for PCR analysis.
Classification of non-Hodgkin's lymphomas
Non-Hodgkin's lymphomas were diagnosed according to the updated Kiel classification. 34 
Cells and cell lines
The human B cell lymphoma line Karpas 422 35 was kindly provided by Dr A Karpas (University of Cambridge, Cambridge, UK). This cell line carries a t(14;18) translocation with a breakpoint in the MBR region of the BCL-2 gene and served as a positive control. DNA prepared from the Burkitt's lymphoma cell line Raji and human placenta were used as negative controls.
DNA isolation
High molecular weight DNA (HMW-DNA or spooled DNA) was prepared from PB or BM cells by standard proteinase K digestion, phenol-chloroform extraction and ethanol precipitation. DNA concentration was determined spectrophotometrically.
The extraction of DNA from formalin-fixed, paraffinembedded lymphoma tissue was based upon procedures already described.
36,37
PCR
The method of semi-nested, two-step PCR amplification of BCL-2/IgH rearrangements with a breakpoint within the MBR region, all measures to avoid or to detect possible contamination and carry-over as well as the electrophoretic and hybridization analysis of amplified products have been described in detail. 24, 30 In standard PCR reactions 1-2 g DNA was used.
Limiting dilution assay
In quantitative assays HMW-DNA was diluted with water and added to the PCR mixture at the following final amounts: 10, 5, 2.5, 1, 0.1, 0.01, 0.001 g and further 10-fold dilutions if necessary. In the case of healthy blood donors the results obtained by this assay have been confirmed by the stochastic multiple-tube approach. 30 
Real-time quantitative PCR
Based on the 5Ј nuclease activity of Taq DNA polymerase, PCR amplification in the presence of a target-specific, double labeled fluorogenic probe allows an automated quantification of the amplification products in real time using the ABI Prism 7700 Sequence Detection System (PE-Applied Biosystems, Foster City, CA, USA). 38 The quantitative detection of t(14;18)-positive cells by this technique has been described previously. 39 For the detection of the t(14;18) translocation by real time quantitative PCR we used the J H -consensus primer (5Ј-ACCTGAGGA-GACGGTGAC-3Ј) and the inner BCL-2 primer (5Ј-TGGGGTTTTGACCTTTAGAGA-3Ј). As the probe we have chosen a 25 bp oligonucleotide that includes the sequence of the 18 q detection oligonucleotide of the twostep PCR (5Ј-CTCTGGGTGGGTCTGTGTTGAAACA-3Ј).
Generation of standard curves
The generation of standard curves has been previously described. 39 Briefly, genomic DNA as well as amplified and cloned DNA fragments from the t(14;18)-positive cell line Karpas 422 and normal PBMC were used in several experiments to establish standard curves for t(14;18), ␤-actin and
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Ki-ras. The results of the real-time quantitative PCR are highly reproducible with initial copy numbers in the range between 10 5 and 5-10. 39 Single copies can be detected, since a sample containing only one copy can be distinguished reliably from a negative one. In addition, appropriate dilutions of standard DNA preparations served as positive controls in quantitative PCR assays.
Nucleotide sequence analyses
The nucleotide sequences of the t(14;18) DNA fragments amplified from each patient were analyzed as previously described. 30 Briefly, t(14;18)-positive DNA fragments were first identified by hybridization, extracted from agarose gels and reamplified. Direct DNA sequencing of the PCR products was performed according to the dideoxy chain termination method with a modified T7 DNA polymerase (SequiTherm Cycle Sequencing Kit; Biozym, Hessisch Ohlendorf, Germany).
Results
Patients studied
Fifteen patients were treated, nine (60%) had a t(14;18)-positive lymphoma (Tables 1 and 2 ). During the course of this study 134 peripheral blood and bone marrow samples were analyzed by standard PCR, 79 samples by quantitative PCR using the limiting dilution assay and 42 samples by real-time quantitative PCR. Patients 10 to 15 have been consistently negative by PCR, even by the stochastic multiple tube approach using up to 10 g DNA per assay.
Overall survival and event-free survival
Ten of 15 patients (67%) are alive after a median followup of 45 months (Figure 1) , two patients are under treatment for relapsed lymphoma. There were two treatmentrelated early deaths during the first 3 months: both patients died from graft failure followed by septic shock and ARDS. A third patient died 2 years after ABMT because of myelodysplasia/AML, two patients from relapse (see also Table 1 ). Event-free survival is 53% after a mean observation period of 4 years.
Comparative sequence analysis of t(14;18) breakpoints on circulating B cells and primary lymphoma tissue
The t(14;18) DNA fragments of the latest follow-up visit after ABMT were sequenced (Table 2 ). In no case did we observe a sequence that was identical to 30 translocations amplified from healthy blood donors 30 or from 22 FL patients controlled by PCR after radiotherapy. 41 In nine patients it was possible to perform PCR and nucleotide sequence analysis on very small amounts of DNA isolated from formalin-fixed, paraffin embedded primary lymphoma tissue. In seven positive cases the same translocation sequence was found in the primary lymphoma tissue and in PBMC during follow-up after ABMT. The time interval between the two samplings was 2-10.5 years with a median of 5.9 years ( Table 2 ). In two negative cases the primary lymphoma tissue as well as all follow-up samples were consistently negative.
PCR assays on PBMC and BM cells before and after purging
All nine patients with circulating t(14;18)-positive cells in the peripheral blood also had PCR-detectable t(14;18)-positive cells in the bone marrow. The harvested bone marrow cells of five of seven patients with histologic bone marrow infiltration were purged because the previous biopsy showed more than 5% lymphoma cells infiltrating the marrow. Three of these five patients were t(14;18)-positive, which allowed us to control the efficacy of purging by quantitative PCR using the limiting dilution assay. Compared to four harvests from histologically non-infiltrated bone marrows, which contained seven to 700 t(14;18)-positive cells per million nucleated cells, these three bone marrow preparations contained 7000 to 70 000 t(14;18)-positive cells per million nucleated cells, as found by PCR (Table  1) . In all three cases, one cycle of purging with four monoclonal antibodies and immunomagnetic beads resulted in a 
Detection of circulating t(14;18)-positive cells after ABMT
In seven of nine t(14;18)-positive patients it was possible to obtain serial blood samples after ABMT for molecular monitoring of t(14;18)-positive cells by PCR (Figure 2) . Unfortunately, only one post-ABMT sample was available from patients Nos 7 and 9, but none during later followup which was carried out far from our center. erally believed to provide only semiquantitative data. Therefore all samples still available were also assayed by real-time quantitative PCR, which provides highly reproducible quantitative results. 39 The number of circulating t(14;18)-positive cells decreased in all patients after ABMT by at least two orders of magnitude and in five of seven cases also to undetectable values. Two t(14;18)-positive patients relapsed (patients 1 and 5). Patient 1 had no PCRdetectable lymphoma cells in her first post-treatment sample (Figure 3a) . Four months after ABMT, seven t(14;18)-positive cells per million PBMC were found, on day 192 7000 t(14;18)-positive cells per million mononuclear cells were detected followed by a further increase. The clinical relapse was diagnosed 9 months after transplantation on day 264. The quantitative PCR analysis had already indicated recurrent disease at day 192 after ABMT.
The limiting dilution assay combined with the two-step PCR and the real-time quantitative PCR of the first two post-ABMT samples of patient 5 gave different results. Both samples were negative for PCR-detectable lymphoma cells by liming dilution and standard PCR, whereas realtime quantitative PCR showed slowly decreasing numbers of t(14;18)-positive cells near the detection limit of the method. In subsequent samples obtained during the second and third year after ABMT both methods showed a slow increase of circulating t(14;18)-positive cells. Twenty-two months after ABMT slightly enlarged iliac lymph nodes were found and the relapse was confirmed. Because of very slowly progressing disease after multiple therapeutic interventions in the past the patient was treated with alpha-interferon, but locally progressing disease was observed in parallel with a further increase of circulating t(14;18)-positive cells. Thirty-two months after ABMT the patient is still alive.
In contrast, in patients in continuous CR after ABMT (patients 2,3,4,6,8) circulating t(14;18)-positive cells were found to be quite stable in number after their reappearance post-ABMT, generally within one order of magnitude.
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Discussion
After a mean observation period of 4 years after ABMT, the overall survival of the 15 patients under study is 67% (10/15) and the event-free survival is 53% (8/15; Figure 1 ).
Five patients in this study showed an infiltration of the bone marrow with lymphoma cells exceeding 5% of nucleated cells. The bone marrow from these patients harvested for ABMT was purged with five monoclonal antibodies and immunomagnetic beads. Quantitative PCR assays carried out on three t(14;18)-positive bone marrow harvests showed a reduction of t(14;18)-positive cells by two orders of magnitude in all instances, but substantial amounts of t(14;18)-positive cells remained in the stem cell preparation, ie 70 to 700 t(14;18)-positive per million nucleated cells.
The value of purging and the role of the extent of tumor cell contamination of the reinfused bone marrow with regard to relapse-free survival is still unclear. [13] [14] [15] Clearly the number of patients is too small for statistically significant results. But interestingly, the two patients (patients 1 and 5) who were reinfused with bone marrow preparations containing the lowest percentage of t(14;18)-positive cells relapsed within the first 2 years after transplantation. In contrast, the remaining five patients (Nos 2, 3, 4, 6 and 8), who received bone marrow preparations containing up to 100 times more t(14;18)-positive cells, are still in CR after almost 4 years.
All patients carrying a PCR-detectable t(14;18)-positive FL were reinfused with autologous bone marrow containing t(14;18)-positive cells. Shortly after myeloablative treatment five of seven patients became t(14;18)-negative in at least one blood sample. In all patients t(14;18)-positive cells reappeared in the circulating blood within 22 months after transplantation, but only two of seven relapsed. Surprisingly, patient No. 6 who had the highest percentage of t(14;18)-positive cells in her reinfused marrow has been consistently t(14;18)-negative in all but one sample obtained after ABMT for almost 3 years. In our study there In addition, the reappearance of circulating t(14;18)-positive cells in all patients demonstrates the limited value of qualitative PCR tests with regard to prognosis (Figure 2) . Therefore, quantitative PCR assays were carried out with DNA prepared from PBMC from seven of nine t(14;18)-positive patients. In summary, we found three different patterns reflecting the clinical course of the disease. After a significant reduction of circulating t(14;18)-positive cells due to high-dose chemotherapy, t(14;18)-positive cells reappeared in all patients within the first 2 years after transplantation. In patients in continuous CR we found that the numbers of t(14;18)-positive cells remained stable within one order of magnitude. In contrast, a relapse can be heralded by or associated with an increase of circulating t(14;18)-positive cells by several orders of magnitude (Figure 3a ). This has also been observed in two patients who relapsed after radiotherapy for low grade FL. 42 The prognostic value of quantitative PCR results is limited by the fact that very slowly progressing disease is accompanied by slowly increasing numbers of t(14;18)-positive cells ( Figure 3C , patient 5). Such findings may be difficult to distinguish from PCR results obtained with blood samples from patients in CR.
With regard to the findings of t(14;18)-positive cells in healthy blood donors and reactive lymphoid tissue it is essential to prove that those t(14;18)-positive cells monitored as MRD during CR are indeed related to the malignant lymphoma cell clone. Ideally, this is done by sequence comparison of DNA fragments amplified from primary lymphoma tissue and from PBMC obtained during CR. In the case of seven of nine t(14;18)-positive patients it was possible to analyze DNA prepared from formalin-fixed, paraffin embedded tissue biopsies obtained at first presentation. The same t(14;18) translocation was found in all cases in the primarily affected tissue as well as in PBMC and bone marrow cells before and after ABMT, as shown by nucleotide sequence analysis (Table 2) .
At present we cannot distinguish between t(14;18)-positive cells belonging to the malignant lymphoma cell clone and their more or less benign ancestors -maybe cells resembling more the t(14;18)-positive cells detected in healthy individuals. At least the nucleotide sequence of the t(14;18) translocation seems to be very stable over many years, as has also been shown in long-lived positive clones in healthy blood donors. 30 Therefore, the identification of additional genetic changes, that are expected to occur in B cells progressing to true lymphoma cells, would be of great importance for diagnostic assays as well as for providing deeper insights into the progression from immortalized B cells -detectable as circulating t(14;18)-positive B cells in almost all healthy individuals -to follicular lymphoma cells.
